249 related articles for article (PubMed ID: 22249159)
1. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Vakana E; Platanias LC
Oncotarget; 2011 Dec; 2(12):1322-8. PubMed ID: 22249159
[TBL] [Abstract][Full Text] [Related]
2. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
3. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
4. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Kharas MG; Fruman DA
Cancer Res; 2005 Mar; 65(6):2047-53. PubMed ID: 15781610
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Vakana E; Altman JK; Glaser H; Donato NJ; Platanias LC
Blood; 2011 Dec; 118(24):6399-402. PubMed ID: 22021366
[TBL] [Abstract][Full Text] [Related]
6. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.
Mayerhofer M; Valent P; Sperr WR; Griffin JD; Sillaber C
Blood; 2002 Nov; 100(10):3767-75. PubMed ID: 12393646
[TBL] [Abstract][Full Text] [Related]
7. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
8. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
11. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
12. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
15. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin as a therapeutic target in leukemia.
Giles FJ; Albitar M
Curr Mol Med; 2005 Nov; 5(7):653-61. PubMed ID: 16305491
[TBL] [Abstract][Full Text] [Related]
17. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
Redig AJ; Vakana E; Platanias LC
Leuk Lymphoma; 2011 Feb; 52 Suppl 1():45-53. PubMed ID: 21299459
[TBL] [Abstract][Full Text] [Related]
18. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
20. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Kharas MG; Janes MR; Scarfone VM; Lilly MB; Knight ZA; Shokat KM; Fruman DA
J Clin Invest; 2008 Sep; 118(9):3038-50. PubMed ID: 18704194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]